Lenvatinib for poorly differentiated carcinoma of the anterior mediastinum

Toyoshi Yanagihara, Kotaro Matsumoto, Reiko Yoneda, Ayaka Egashira, Hiroshi Mannoji, Hiroko Watanabe, Katsuzo Hanaoka, Yuuka Nakayama, Naruhiko Ogo, Yu Inutsuka, Tatsuma Asoh, Kenichi Kohashi, Izumi Kinoshita, Yoshinao Oda, Takashige Maeyama

Research output: Contribution to journalArticlepeer-review

Abstract

We describe a Case of a 74-year-old Japanese man with poorly differentiated carcinoma of the anterior mediastinum. The patient underwent anterior mediastinal tumor resection through median sternotomy. The tumor, 7.0 × 5.0 cm, had invaded surrounding tissues (pericardium, right lung, right and left brachiocephalic veins, and superior vena cava). Complete resection of the tumor was not performed. One month after the operation, the patient developed multiple pulmonary metastases, right pleural dissemination, and carcinomatous pleurisy. He was treated with lenvatinib, a novel multi-kinase inhibitor, to which the metastasis responded favorably. This case reports for the first time the clinical usefulness of lenvatinib for poorly differentiated carcinoma of the anterior mediastinum. Management of side effects by several methods, including suspending use of medication on weekends (called a weekends-off strategy), is another strong argument to continue lenvatinib administration.

Original languageEnglish
Article number101477
JournalRespiratory Medicine Case Reports
Volume33
DOIs
Publication statusPublished - Jan 2021

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Lenvatinib for poorly differentiated carcinoma of the anterior mediastinum'. Together they form a unique fingerprint.

Cite this